TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31049877
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (n = 137, 20 g of whey protein, 3 g of leucine, 800 IU VitD)
Study: 20431381
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg/m loading dose on day 1, then 50 mg/m daily, maximum 70 mg/d)
Study: 20431381
Drug: L-AmB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AmB (3 mg/kg daily)
Study: 12518369
Drug: L-AmB
Normalized name: All-ambo-5-((4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)phenyl)methyl)-1,3-thiazole-2,4(3H,5H)-dione
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AmB
Study: 12138325
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg under fasting conditions
Study: 12138325
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg under fed conditions
Study: 7543083
Drug: 50 mmol
Normalized name: dibasic potassium phosphate 150 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mmol magnesium sulfate infusion over 20 hours
Study: 2475689
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg verapamil HCl sustained‐release tablet (Isoptin SR 240, Securon SR)
Study: 2475689
Drug: two half
Approvals — FDA: no, EMA: no, PMDA: no
Description: two half 240‐mg verapamil HCl sustained‐release tablets (2 X half 240‐mg tablets, Study 1)
Study: 2475689
Drug: two 120-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 120-mg verapamil HCl sustained‐release tablets (Isoptin SR 120) (2 X 120 mg, Study 2)
Study: 31808151
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg.kg-1
Study: 29277690
Drug: Long-acting β2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2 agonists, long-acting muscarinic antagonists (LABAs or LAMAs), LABA/LAMA combination QVA149
Study: 29277690
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (including LABA/LAMA)
Study: 25644340
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain (WG) diet (>80 g/d)
Study: 25644340
Drug: Refined grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined grain (RG) diet (<16 g/d)
Study: 18315425
Drug: Ultrasonic instrumentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic instrumentation plus application of an 8.8% doxycycline gel
Study: 18315425
Drug: Adjunctive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antibiotic therapy (doxycycline)
Study: 17195531
Drug: Xenical (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenical (120 mg 3 times a day) with moderate hypocaloric diet
Study: 6204202
Drug: Positive food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive food challenges (up to 8 g of dehydrated food)
Study: 29547834
Drug: Tailored FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored FEC (E 75-90 mg/m2, C 900-1200 mg/m2)
Study: 29547834
Drug: Standard FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FEC (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Study: 18833128
Drug: Haloinhalation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloinhalation therapy
Study: 2317421
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 90 minutes
Study: 2317421
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for 120 minutes
Study: 2317421
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream applied for less than 120 minutes
Study: 24099414
Drug: Family supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family supportive therapy with generic information
Study: 20840875
Drug: Standard cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cancer treatments (controls)
Study: 16223206
Drug: rifaximin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rifaximin 1,200 mg/day
Study: 16223206
Drug: lactulose 10-20
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lactulose 10-20 g three times daily
Study: 10550153
Drug: 13‐cis‐retinoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐cis‐retinoic acid (13‐CRA) 30 mg orally daily for 6 months
Study: 7495926
Drug: Flumazenil 2
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 2 mg
Study: 2180267
Drug: Control agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control agents (cholestyramine, fibrates, probucol)
Study: 424477
Drug: active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active medication (alpha‐flupenthixol)
Study: 28953616
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg) administered 30 minutes before induction of anesthesia
Study: 28953616
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg) administered immediately after induction of anesthesia
Study: 23368980
Drug: Opioids (morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (morphine, oxycodone)
Study: 21425574
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic treatment + fluid resuscitation)
Study: 19588638
Drug: Fixed-combination gel
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination gel containing BPO 5% and clindamycin 1% (BPO/C) plus tretinoin microsphere gel 0.04% (RAM)
Study: 19588638
Drug: Fixed-combination gel
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination gel containing clindamycin phosphate 1.2% and tretinoin 0.025% (CPT) plus a once-daily BPO 5% wash
Study: 7813389
Drug: L-acetylcarnitine (LAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (LAC) 1500 mg/day for 90 days
Study: 7813389
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 30 days (phase T0) and further 30 days of placebo treatment (phase T3)
Study: 2887614
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine at night
Study: 25752401
Drug: PET-based isotoxic
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-based isotoxic accelerated radiation therapy (PET-ART)
Study: 25752401
Drug: Conventional fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fixed-dose CT-based radiation therapy (CRT)
Study: 21406465
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg) administered 1 hour before stress
Study: 18201356
Drug: PUVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment twice/week
Study: 18201356
Drug: PUVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment three times/week
Study: 15356084
Drug: DHEA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100 mg/d, 3 months)
Study: 11458055
Drug: 3-month neoadjuvant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Study: 11458055
Drug: 8-month neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-month neoadjuvant hormonal therapy (7.5 mg leuprolide intramuscularly monthly and 250 mg flutamide orally 3 times daily)
Study: 11458055
Drug: 3-month neoadjuvant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month neoadjuvant hormonal therapy
Study: 11458055
Drug: 8-month neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-month neoadjuvant hormonal therapy
Study: 9558128
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg VPA daily
Study: 9558128
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg VPA daily
Study: 2977273
Drug: Zoladex 3.6
Normalized name: Zoladex 3.6mg Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex 3.6 mg depot
Study: 2977273
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) 3 mg/day
Study: 28873028
Drug: Single intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraoperative dose of IV acetaminophen
Study: 28873028
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative pain regimen (oral acetaminophen and ibuprofen)
Study: 27074894
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 40 mL of 0.375% levobupivacaine and morphine patient‐controlled analgesia
Study: 27074894
Drug: Morphine patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient‐controlled analgesia (Control)
Study: 25879867
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MVA
Study: 11367650
Drug: Huancongdan (HCD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huancongdan (HCD) capsule
Study: 8156307
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg/day for 2 weeks, then 11 weeks off etidronate; four cycles total) + Prednisone
Study: 3045423
Drug: Adjuvant CYVADIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CYVADIC chemotherapy (cyclophosphamide, vincristine, Adriamycin, and dacarbazine)
Study: 3045423
Drug: Adjuvant VAC
Normalized name: VAC-52150
DrugBank: VAC-52150 (DB17781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant VAC chemotherapy (vincristine, actinomycin-D, and cyclophosphamide)
Study: 31820593
Drug: Oxycodone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.1 mg/kg
Study: 23549409
Drug: Encapsulated oral
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated oral supplement of Bifidobacterium infantis 35624
Study: 17126655
Drug: Hypothermic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic patients (oral body temperature <35.8 degrees C)
Study: 17126655
Drug: Nonhypothermic patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonhypothermic patients (oral body temperature ≥35.8 degrees C)
Study: 11314621
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia (nalbuphine HCl and ketorolac tromethamine)
Study: 11314621
Drug: Conventional pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional pethidine HCl intramuscular group
Study: 9146938
Drug: Topical azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical azelastine (0.254 mg per nasal cavity)
Study: 9146938
Drug: Oral cetirizine
Normalized name: cetirizine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cetirizine (10 mg)
Study: 24147933
Drug: ATX‐101 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX‐101 (1 mg cm(‐2))
Study: 24147933
Drug: ATX‐101 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX‐101 (2 mg cm(‐2))
Study: 22571072
Drug: Structured information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured information (short video about practical aspects of the hospital stay, surgical and adjuvant treatment)
Study: 20154074
Drug: 100% nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% nitrogen through a 40% venturi mask at a flow rate of 10 L/min for 2 h
Study: 14661284
Drug: Uninformed patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninformed patients waiting for i.v. contrast material injection
Study: 8841209
Drug: Propranolol 2
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 2 mg IV
Study: 1365676
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (100 mg/serving) under forced-choice condition
Study: 6384434
Drug: Metronidazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (6 g/m2 given 4 hr before each of the first 3 doses of RT)
Study: 6384434
Drug: Metronidazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (6 g/m2)
Study: 25956661
Drug: Tavaborole topical
Normalized name: tavaborole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tavaborole topical solution, 5%
Study: 17187609
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychological treatment and physiotherapy (Group A)
Study: 17187609
Drug: Integrated combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated combination of psychological treatment and somatic treatment (Group C)
Study: 15727400
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 mcg/kg) plus midazolam (0.02 mg/kg)
Study: 15727400
Drug: Meperidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.5 mg/kg) plus midazolam (0.02 mg/kg)
Study: 31197361
Drug: bmMSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bmMSC therapy
Study: 28087178
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (bilateral Five Shu in Spleen Meridian), once daily for 10 consecutive days.
Study: 28087178
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (same acupoints using Park Sham Device), once daily for 10 consecutive days.
Study: 17096621
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions including counseling, education, self‐medication programs, cues and organizers, and decreasing dosing frequency.
Study: 17096621
Drug: Decreasing dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreasing dosing frequency and self‐medication programs.
Study: 14755979
Drug: Physical exercises
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercises 3‐5 times/week, 45‐60 min. per session, combined with antihypertensive drug therapy (Group B)
Study: 14755979
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug therapy only (Group C)
Study: 14755979
Drug: Physical exercises
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercises and antihypertensive therapy (Group B)
Study: 10727313
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg cyclosporine microemulsion daily
Study: 10727313
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg cyclosporine microemulsion daily
Study: 1552913
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (0.4 g per kilogram per day)
Study: 1552913
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (200 to 250 ml per kilogram of body weight)
Study: 31053142
Drug: 3 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 standard doses of HBV vaccination (20 μg at month 0, 1, 6)
Study: 31053142
Drug: 4 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 standard doses of HBV vaccination (20 μg at month 0, 1, 2, 6)
Study: 31053142
Drug: 3 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 standard doses of HBV vaccination
Study: 31053142
Drug: 4 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 standard doses of HBV vaccination
Study: 29748420
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote ischaemic conditioning (rIC) for 4 weeks starting on day 3 post P‐PCI
Study: 29748420
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote ischaemic conditioning (rIC)
Study: 28256813
Drug: BUP-MOR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-MOR group (3 mg bupivacaine + 50 mcg morphine)
Study: 28256813
Drug: BUP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP group (5 mg bupivacaine)
Study: 17387332
Drug: Active nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active nicotine replacement therapy transdermal patch
Study: 17268395
Drug: Newer M3
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer M3 receptor selective anticholinergics (solifenacin, darifenacin)
Study: 12830340
Drug: Benazepril and
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril and Amlodipine combination o.d.
Study: 11273913
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia (TEA) combined with general anesthesia (GA) using bupivacaine 0.5% and low-dose isoflurane (0.3-0.5 vol%)
Study: 24993695
Drug: green-plant membranes
Approvals — FDA: no, EMA: no, PMDA: no
Description: green-plant membranes (5 g)
Study: 17252888
Drug: Twice‐daily atomoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily atomoxetine
Study: 17252888
Drug: Thrice‐daily methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice‐daily methylphenidate
Study: 14501737
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg daily (40 mg twice daily for 12 weeks)
Study: 9217897
Drug: Acute insulin-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute insulin-glucose infusion followed by multidose subcutaneous insulin
Study: 9217897
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intensive insulin treatment)
Study: 29477588
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral rTMS (n = 20)
Study: 27496229
Drug: Semi-individualised Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-individualised Chinese medicine treatment for 48 weeks
Study: 23836493
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aerobic and Resistance Training (AT+RT)
Study: 20565376
Drug: Genzyme (Thymoglobulin:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genzyme (Thymoglobulin: ATG‐G; 6.2 +/‐ 2.9 mg/kg for 7 days)
Study: 20565376
Drug: Fresenius (Lymphoglobulin:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresenius (Lymphoglobulin: ATG‐F; 22.6 +/‐ 7.9 mg/kg for 6 days)
Study: 18988154
Drug: Azithromycin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.5% eye-drops, twice daily for 3 days
Study: 18988154
Drug: Tobramycin 0.3%
Normalized name: TOBRAMYCIN 0.3% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3% eye-drops, every 2 hours while awake for 2 days, then four times daily for 5 days
Study: 20159729
Drug: Danqi Huogan
Normalized name: Menthol 30 mg TOPICAL PATCH [Alhua Huogan Pain Relieving Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danqi Huogan Capsule in addition to routine therapies
Study: 20159729
Drug: Routine therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapies for liver protection
Study: 8005276
Drug: Depot form
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot form of triptoreline (3.75 mg IM injection)
Study: 8005276
Drug: Standard release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard release form of triptoreline (0.1 mg SC daily)
Study: 11726845
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG solution
Study: 27084279
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) + photodynamic therapy + oral hygiene (OH)
Study: 27084279
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) + oral hygiene (OH)
Study: 22797283
Drug: Magnesium lozenges,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium lozenges, administered 30 min preoperatively.
Study: 22797283
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group), administered 30 min preoperatively.
Study: 12204499
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg/day)
Study: 16003289
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (SJW) 300 mg LI 160 3 times daily
Study: 12462291
Drug: Interferon alpha-n2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-n2b (5 MU subcutaneously once daily for 8 weeks, then 5 MU TIW for 48 weeks if HCV-RNA negative)
Study: 12462291
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (males without a history of drug addiction)
Study: 7473012
Drug: Fiber therapy
Normalized name: Fiber Therapy
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber therapy alone for 10 days (F)